1Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women[ J]. Clin Endocrinol Metab, 1999,84 : 165-169. 被引量：1
2De Leo V. La Marca A, Petraglia F, et al. Insulin-lowering agents in the management of polycystic ovary syndrome[ J ]. Endocr Rev ,2003,24:633-667. 被引量：1
3Dunaif A, Nedscape. Drug insight:insulin-sensitizing drugs in the treatment of polycystic ovary syndrome-a reappraisal[ J]. Nat Clin Pract Indrocrinol Metab ,2008,4(5 ) :272-283. 被引量：1
4Welch S, Gebhart SS, Bergman RN, et al. Model analysis of intravenous glucose tolerance test derived insulin sensitivity in diabetic subjects[J]. Clin Endocrinol Metab,1990,71:1508-1518. 被引量：1
5Reaven GM. Role of insulin in human disease [ J ]. Diabetes, 1988,37 ( 12 ) : 1595-1607. 被引量：1
6Groop L, Forsblom C, Lehtovirta M, et al. Metabolic consequences of a family history of NIDDM [ J]. Diabetes, 1996,45 : 1585-1593. 被引量：1
7Teede H J, Meyer C, Norman RJ. Insulin-sensitisers in the treatment of polycystic ovary syndrome[ J]. Expert Opin Pharmacother, 2005,6:2419-2427. 被引量：1
8Kodaman PH, Duleba AJ. Statins in the treatment of polycystic ovary. syndrome [ J ]. Semin Reprod Med,2008,26 ( 1 ) : 127-138. 被引量：1
9Wild RA. Coronary. artery caleification and osteoporosis: is estrogen an important link? [J]. Menopause, 2005,12:661-663 被引量：1
10Talbott E, Clerici A, Berga SL, et al. Adverse lipid and coronary heart disease risk profiles in young women with polyeystic ovary syndrome: results of a case-control study [ J]. Clin Epidemiol, 1998,51:415-422. 被引量：1
